Global antacid market is projected to grow at a considerable CAGR of 4.8% during the forecast period (2024-2031). The market growth is driven by the increase in the prevalence of gastric diseases due to changing dietary habits, demanding enhanced gastric solutions for acidity and heartburn. Additionally, the advancement of the e-commerce industry coupled with the consumer preference for online medication is significantly propelling the market growth. Moreover, the population with Gastroesophageal Reflux Disease (GERD) has increased significantly resulting in the increasing demand for antacids across the globe.
Browse the full report description of “Antacid Market Size, Share & Trends Analysis Report by Drug Class (Proton Pump Inhibitor, H2 Antagonist, and Acid Neutralizers) and by Formulation Type (Tablet, Liquid, and Powder) and Forecast, 2024-2031” at https://www.omrglobal.com/industry-reports/antacid-market
The global antacid market is segmented by drug class (proton pump inhibitor, H2 antagonist, and acid neutralizers) formulation type (tablet, liquid, and powder), and geographies (North America, Europe, Asia-Pacific, and the Rest of the World).
Market Dynamics
- The acid neutralizers segment is expected to register significant growth in the market during the forecast period, as it provides rapid relief against heartburns and acidity. Moreover, the availability of acid neutralizers in various flavors and formulations tends to drive the market share of acid neutralizers.
- The liquid segment is expected to present significant growth as it is a widely preferred solution among infants and geriatric populations for acidity and heartburns, owing to ease of intake and palatable taste.
- Asia-Pacific is expected to register considerable growth in the market, owing to rising consumer awareness, continuous investment by market players, and growing disposable income. In addition, the presence of key players such as GlaxoSmithKline PLC has increased the availability of effective treatment methods that foster the growth of the regional market.
The major players in the global antacid market include GlaxoSmithKline PLC, Abbott Laboratories, Reckitt Benckiser Group PLC, Bayer AG, Sanofi SA, Pfizer Inc., and The Procter & Gamble Co., among others. The market players are contributing significantly to the market growth, by the adoption of various business strategies, such as collaborations, mergers and acquisitions, product portfolio diversification, and more.
Recent Developments
- In June 2024, Akums Drugs & Pharmaceuticals Ltd launched an advanced anti-reflux antacid - sodium alginate + potassium bicarbonate chewable tablet, approved by the Drugs Controller General of India (DCGI). The chewable tablet is a reflux suppressant, and each tablet contains sodium alginate IP 500mg and potassium bicarbonate IP 100mg.
- In June 2024, a global study and meta-analysis led by researchers at McMaster University, investigated the effect of the gastric acid suppressant pantoprazole, on patients in the intensive care unit (ICU) who need a breathing machine?(mechanical ventilator), to prevent upper gastrointestinal bleeding, caused by stress-induced ulcers in the stomach.??
- In April 2024, the National Advertising Division (NAD) addressed the Wonderbelly Antacid challenge, where the company marketed its antacids as the ‘clean’ alternative. NAD added the ‘Wonderbelly Antacid’ indicates relief from ‘heartburn, acid indigestion, and sour stomach'. However, Wonderbelly alleviates symptoms felt in the stomach. Thus, NAD concluded that reasonable consumers would not be deceived by the ‘belly claims’.
- In September 2023, the Goa state government warned the local unit of Abbott Laboratories to suspend the manufacturing license of its antacid medicine, as the factory depicted contamination risks and sanitization issues.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/antacid-market